Stockscreener 앱 받기
8.92
1.55%
-0.14
시장 영업 전:
9.00
0.08
+0.90%
전일 마감가:
$9.06
열려 있는:
$9.09
하루 거래량:
3.58M
Relative Volume:
0.70
시가총액:
$2.27B
수익:
$885.72M
순이익/손실:
$-457.98M
주가수익비율:
-5.0211
EPS:
-1.7765
순현금흐름:
$293.05M
1주 성능:
+7.08%
1개월 성능:
-1.11%
6개월 성능:
+19.41%
1년 성능:
-13.31%
1일 변동 폭
$8.795
$9.18
1주일 범위
$8.10
$9.18
52주 변동 폭
$6.00
$10.32
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.92 | 2.30B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 재개 | Evercore ISI | Outperform |
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
BIOCRYST (BCRX) director Jill Milne granted RSUs and options in board compensation - Stock Titan
BioCryst (BCRX) director receives stock grants and options, updates trust holdings - Stock Titan
BioCryst (BCRX) director receives RSU and option grants under board plan - Stock Titan
BioCryst (BCRX) director Steven Frank awarded RSUs and stock options - Stock Titan
BioCryst (NASDAQ: BCRX) director awarded RSUs and stock options as compensation - Stock Titan
BioCryst (BCRX) director Vincent Milano receives stock and option grants - Stock Titan
BioCryst (BCRX) director receives stock units and options grants - Stock Titan
Biocryst (NASDAQ: BCRX) director receives stock units and options grant - Stock Titan
Biocryst (BCRX) grants Theresa Heggie RSUs and stock options as board pay - Stock Titan
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up (BCRX) - Seeking Alpha
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (NASDAQ: BCRX) investors approve 7M-share stock incentive plan - Stock Titan
Sector Update: Healthcare Stocks Advance Pre-Bell Friday - Moomoo
BioCryst Advances HAE Treatments with New Clinical Data (BCRX) - GuruFocus
BioCryst highlights efficacy gains across hereditary angioedema portfolio - grafa.com
BioCryst presents new data on HAE therapies at EAACI meeting - Investing.com
BioCryst presents new data on HAE therapies at EAACI meeting By Investing.com - Investing.com Canada
Oral HAE drug reduces child attacks; new antibody data across patient subgroups - Stock Titan
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Yahoo Finance
BioCryst Pharmaceuticals Grants Stock Options and RSUs to New Employees - Quiver Quantitative
Nine new BioCryst hires receive stock options, RSUs as inducement - Stock Titan
How Biocryst Pharmaceuticals Inc. (BCRX) Affects Rotational Strategy Timing - Stock Traders Daily
Do BioCryst’s EAACI 2026 HAE Data Plans Subtly Recast the BCRX Long-Term Innovation Story? - Sahm
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances - MarketBeat
BCRX Technical Analysis | Trend, Signals & Chart Patterns | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
Earnings call transcript: BioCryst Q1 2026: EPS Miss, Revenue Beat - Investing.com
BCRX: ORLADEYO and navenibart drive rare disease growth, with key milestones and profitability ahead - TradingView
BIOCRYST (BCRX) Board Chair Vincent Milano receives stock grant as retainer pay - Stock Titan
BioCryst (BCRX) director awarded stock in lieu of cash retainer - Stock Titan
BioCryst (BCRX) director Jill C. Milne receives 1,262-share stock grant as board retainer - Stock Titan
Biocryst (BCRX) director takes share grant instead of cash fee - Stock Titan
BIOCRYST (BCRX) director Steven Frank granted 1,262 shares instead of $11,250 cash - Stock Titan
These 10 mid-cap U.S. healthcare companies rank among the market's most attractively valued stocks - Seeking Alpha
Could BioCryst (BCRX) HAE Data at EAACI Quietly Redefine Its Core Investment Story? - Sahm
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Mixed Returns Temper Its Rare Disease Upside Narrative - Sahm
New ORLADEYO HAE data in children, adults to debut in Istanbul - Stock Titan
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewswire
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
BCRX Should I Buy - Intellectia AI
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
BioCryst director Amy McKee sells $100,284 in company shares - Investing.com UK
BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan
Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.11%
자본화:
|
볼륨(24시간):